Современные возможности изменения образа жизни и терапии статинами в профилактике сердечно-сосудистых заболеваний

1. Townsend N, Wilson L, Bhatnagar P et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016; 37 (42): 3232–45.
2. Российский статистический ежегодник. 2016. / Russian Statistical Yearbook. 2016. [in Russian]
3. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Cl in Proc 2011; 86: 304–14.
4. National Institute for Health and Care Excellence. NICE Publ ic Health Guidance 25. June 2010. https://www.nice.org.uk/guidance/ph25
5. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37: 2315–81. DOI: 10.1093/eurheartj/ehw106.
6. Sharma S, Merghani A, Mont L. Exercise and the heart: the good, the bad, and the ugly. Eur Heart J 2015; 36: 1445–53.
7. Katzmarzyk PT, Lee IM. Sedentary behaviour and life expectancy in the USA: a cause-deleted life table analysis. BMJ Open 2012; 2: e000828.
8. Бубнова М.Г., Аронов Д.М. Методические рекомендации. Обеспечение физической активности граждан, имеющих ограничения в состоянии здоровья. Под ред. С.А.Бойцова. Кардиосоматика. 2016; 1: 5–50. / Bubnova M.G., Aronov D.M. Methodic recommendations. Maintaining physical activity of those with limitations in health. Edited by S.A.Boytsov. CardioSomatics. 2016; 7 (1): 5–50. [in Russian]
9. Li Y, Hruby A, Bernstein AM et al. Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease. A Prospective Cohort Study. JACC 2015; 66 (14): 1538–48.
10. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a metaanalysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 1146–55.
11. Chinen I, Shimabukuro M, Yamakawa K et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007; 148: 160–5.
12. Artwohl M, Lindenmair A, Sexl V et al. Different mechanisms of saturated versus polyunsaturated FFA-induced apoptosis in human endothelial cells. J Lipid Res 2008; 49: 2627–40.
13. Hu FB, Manson JA, Willett WC. Types of dietary fat and risk of coronary heart disease: a critical review. Am J Clin Nutr 2001; 20 (1): 5–19.
14. Stentz FB, Kitabchi AE. Palmitic acid-induced activation of human T-lymphocytes and aortic endothelial cells with production of insulin receptors, reactive oxygen species, cytokines, and lipid peroxidation. Biochem Biophys Res Commun 2006; 346: 721–6.
15. Spigoni V, Fantuzzi F, Fontana A et al. Stearic acid at physiologic concentrations induces in vitro lipotoxicity in circulating angiogenic cells. Atherosclerosis 2017; 265: 162–71.
16. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010; 92: 1189–96.
17. Estruch R, Ros E, Salas-Salvado J et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279–90.
18. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002; 16: 761–70.
19. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004; 328: 1519.
20. Weintraub WS, Klein LW, Seelaus PA et al. Importance of total life consumption of cigarettes as a risk factor for coronary artery disease. Am J Cardiol 1985; 55: 669–72.
21. Waters D, Lesperance J, Gladstone P et al. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation 1996; 94: 614–21.
22. Hasdai D, Garratt KN, Grill DE et al. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997; 336: 755–61.
23. Frey P, Waters DD, DeMicco DA. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trials). Am J Cardiol 2011; 107: 145–50.
24. Бубнова М.Г., Аронов Д.М., Красницкий В.Б. Влияние курения на клинические эффекты годичной программы физической реабилитации больных трудоспособного возраста, перенесших острый инфаркт миокарда. CardioСоматика. 2017; 8 (2): 20–9. / Bubnova M.G., Aronov D.M., Krasnitskii V.B. The influence of smoking on the clinical effects of a one-year program of physical rehabilitation of patients of working age who underwent acute myocardial infarction. Cardiosomatics. 2017; 8 (2): 20–9. [in Russian]
25. Prugger Ch, Wellmann J, Heidrich J et al on behalf of the EUROASPIRE Study Group. Passive smoking and smoking cessation among Patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. Eur Heart J 2014; 35: 590–8. DOI: 10.1093/eurheartj/eht538.
26. Бокерия Л.А., Аронов Д.М., Барбараш О.Л. и др. Российские клинические рекомендации. Коронарное шунтирование больных ишемической болезнью сердца: реабилитация и вторичная профилактика. CardioСоматика. 2016; 7 (3–4): 5–71. / Bokeriya L.A., Aronov D.M. et al. Russian clinical guidelines. Coronary artery bypass grafting in patients with ischemic heart disease: rehabilitation and secondary prevention. Cardiosomatics. 2016; 7 (3–4): 5–71. [in Russian]
27. Gambardella J, Sardu C, Sacra C, Santulli G. Quit smoking to outsmart atherogenesis: Molecular mechanisms underlying clinical evidence. Atherosclerosis 2017; 257: 242–5. http://dx.doi.org/10.1016/j.atherosclerosis. 2016.12.010
28. De Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012; 367: 1397–406.
29. Bell JA, Hamer M, Sabia S et al. The natural course of healthy obesity over 20 years. J Am Coll Cardiol 2015; 65: 101–2.
30. Шальнова С.А., Деев А.Д., Баланова Ю.А. и др. Двадцатилетние тренды ожирения и артериальной гипертонии и их ассоциации в России. Кардиоваскулярная терапия и профилактика. 2017; 4: 4–10. / Shal'nova S.A., Deev A.D., Balanova Iu.A. i dr. Dvadtsatiletnie trendy ozhireniia i arterial'noi gipertonii i ikh assotsiatsii v Rossii. Kardiovaskuliarnaia terapiia i profilaktika. 2017; 4: 4–10. [in Russian]
31. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults JACC, 2017. DOI: 10.1016/j.jacc.2017.11.006.
32. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.
33. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290–300.
34. Метельская В.А., Шальнова С.А., Деев А.Д. и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016; 19 (1): 15–23. / Metel'skaia V.A., Shal'nova S.A., Deev A.D. i dr. Analiz rasprostranennosti pokazatelei, kharakterizuiushchikh aterogennost' spektra lipoproteinov, u zhitelei Rossiiskoi Federatsii (po dannym issledovaniia ESSE-RF). Profilakticheskaia meditsina. 2016; 19 (1): 15–23. [in Russian]
35. Kotseva K, Wood D, De Bacquer D et al. EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636–48.
36. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J 2016; 37: 2999–3058. DOI: 10.1093/eurheartj/ ehw272.
37. Ежов М.В., Сергиенко И.В., Аронов Д.М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации IV пересмотра. Атеросклероз и дислипидемии. 2017; 3: 5–22. / Ezhov M.V., Sergienko I.V., Aronov D.M. i dr. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii IV peresmotra. Ateroskleroz i dislipidemii. 2017; 3: 5–22. [in Russian]
38. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46: 1855–62.
39. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–97.
40. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81.
41. Preis SR, Hwang SJ, Coady S et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009; 119: 1728–35.
42. Chodick G, Shalev V, Gerber Y et al. Longterm persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30: 2167–79.
43. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C–60C.
44. Семенова А.Е., Сергиенко И.В. Место питавастатина в лечении и профилактике сердечно-сосудистых заболеваний. Атеросклероз и дислипидемии. 2017; 3: 33–45. / Semenova A.E., Sergienko I.V. Mesto pitavastatina v lechenii i profilaktike serdechno-sosudistykh zabolevanii. Ateroskleroz i dislipidemii. 2017; 3: 33–45. [in Russian]
45. Catapano AL. Pitavastatin: a different pharmacological profile. Clin Lipidol 2012; 7 (3): 3–9.
46. Катапано А., Кухарчук В.В., Сергиенко И.В. и др. Питавастатин – современный статин для коррекции дислипидемии и риска сердечно-сосудистых осложнений. Резолюция экспертного совета. Атеросклероз и дислипидемии. 2017; 2: 104–6. / Katapano A., Kukharchuk V.V., Sergienko I.V. i dr. Pitavastatin – sovremennyi statin dlia korrektsii dislipidemii i riska serdechno-sosudistykh oslozhnenii. Rezoliutsiia ekspertnogo soveta. Ateroskleroz i dislipidemii. 2017; 2: 104–6. [in Russian]
47. Pelliccia F, Rosano G, Marazzi G et al. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual anti platelet therapy. Circ J 2014; 78 (3): 679–84.
48. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009; 25: 2755–64.
49. Teramoto T. Pitavastatin: cl inical effects from the LIVES Study. Atheroscler (Suppl.) 2011; 12: 285–8.
50. Maruyama T, Takada M, Nishibori Y et al. Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study. Circ J 2011; 75 (8): 1951–9.
51. Инструкция по медицинскому применению лекарственного препарата Ливазо. РУ ЛП-002855–090215. / Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Livazo. RU LP-002855–090215. [in Russian]
52. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dysli pidemia. Clin Lipidol 2009; 4 (3): 291–302.
53. Borghi C, Cicero AFG. Which statin is the ideal statin for poly medicated patients? Clin Lipidol 2012; 7 (3): s11–s6.
54. Hiro T, Kimura T, Morimoto T et al; JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009; 54: 293–302.
55. Kodama K, Komatsu S, Ueda Y et al. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound – the TOGETHAR trial. Circ J 2010; 74 (9): 1922–8.
56. Maruyama T, Takada M, Nishibori Y et al. Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study. Circ J 2011; 75 (8): 1951–9.
57. Takayama K, Taki W, Toma N et al. Effect of Pitavastatin on Preventing Ischemic Complications with Carotid Artery Stenting: A Multicenter Prospective Study – EPOCH-CAS Study. Cardiovasc Intervent Radiol 2014; 37: 1436–43. DOI: 10.1007/s00270-013-0813-x.
58. Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholestero – lemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther 2011; 9 (5): 555–62.
59. Kurihara Y, Douzono T, Kawakita K et al. A large-scale, prospective post-marketing surveillance of pitavastatin (LIVALOTM Tablet) – Drug use investigation. Jpn Pharmacol Ther 2007; 35: 9–40.
60. Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv Ther 2011; 28 (9): 799–810.
61. Гиляревский С.Р., Кузьмина И.М., Голшмид М.В. и др. Применение питавастатина у лиц пожилого и старческого возраста: оптимальное соотношение пользы и риска. Атеротромбоз. 2016; 2: 106–16. / Giliarevskii S.R., Kuz'mina I.M., Golshmid M.V. i dr. Primenenie pitavastatina u lits pozhilogo i starcheskogo vozrasta: optimal'noe sootnoshenie pol'zy i riska. Aterotromboz. 2016; 2: 106–16. [in Russian]

________________________________________________

1. Townsend N, Wilson L, Bhatnagar P et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016; 37 (42): 3232–45.
2. Russian Statistical Yearbook. 2016. [in Russian]
3. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Cl in Proc 2011; 86: 304–14.
4. National Institute for Health and Care Excellence. NICE Publ ic Health Guidance 25. June 2010. https://www.nice.org.uk/guidance/ph25
5. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37: 2315–81. DOI: 10.1093/eurheartj/ehw106.
6. Sharma S, Merghani A, Mont L. Exercise and the heart: the good, the bad, and the ugly. Eur Heart J 2015; 36: 1445–53.
7. Katzmarzyk PT, Lee IM. Sedentary behaviour and life expectancy in the USA: a cause-deleted life table analysis. BMJ Open 2012; 2: e000828.
8. Bubnova M.G., Aronov D.M. Methodic recommendations. Maintaining physical activity of those with limitations in health. Edited by S.A.Boytsov. CardioSomatics. 2016; 7 (1): 5–50. [in Russian]
9. Li Y, Hruby A, Bernstein AM et al. Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease. A Prospective Cohort Study. JACC 2015; 66 (14): 1538–48.
10. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a metaanalysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 1146–55.
11. Chinen I, Shimabukuro M, Yamakawa K et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007; 148: 160–5.
12. Artwohl M, Lindenmair A, Sexl V et al. Different mechanisms of saturated versus polyunsaturated FFA-induced apoptosis in human endothelial cells. J Lipid Res 2008; 49: 2627–40.
13. Hu FB, Manson JA, Willett WC. Types of dietary fat and risk of coronary heart disease: a critical review. Am J Clin Nutr 2001; 20 (1): 5–19.
14. Stentz FB, Kitabchi AE. Palmitic acid-induced activation of human T-lymphocytes and aortic endothelial cells with production of insulin receptors, reactive oxygen species, cytokines, and lipid peroxidation. Biochem Biophys Res Commun 2006; 346: 721–6.
15. Spigoni V, Fantuzzi F, Fontana A et al. Stearic acid at physiologic concentrations induces in vitro lipotoxicity in circulating angiogenic cells. Atherosclerosis 2017; 265: 162–71.
16. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010; 92: 1189–96.
17. Estruch R, Ros E, Salas-Salvado J et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279–90.
18. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002; 16: 761–70.
19. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004; 328: 1519.
20. Weintraub WS, Klein LW, Seelaus PA et al. Importance of total life consumption of cigarettes as a risk factor for coronary artery disease. Am J Cardiol 1985; 55: 669–72.
21. Waters D, Lesperance J, Gladstone P et al. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation 1996; 94: 614–21.
22. Hasdai D, Garratt KN, Grill DE et al. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997; 336: 755–61.
23. Frey P, Waters DD, DeMicco DA. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trials). Am J Cardiol 2011; 107: 145–50.
24. Bubnova M.G., Aronov D.M., Krasnitskii V.B. The influence of smoking on the clinical effects of a one-year program of physical rehabilitation of patients of working age who underwent acute myocardial infarction. Cardiosomatics. 2017; 8 (2): 20–9. [in Russian]
25. Prugger Ch, Wellmann J, Heidrich J et al on behalf of the EUROASPIRE Study Group. Passive smoking and smoking cessation among Patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. Eur Heart J 2014; 35: 590–8. DOI: 10.1093/eurheartj/eht538.
26. Bokeriya L.A., Aronov D.M. et al. Russian clinical guidelines. Coronary artery bypass grafting in patients with ischemic heart disease: rehabilitation and secondary prevention. Cardiosomatics. 2016; 7 (3–4): 5–71. [in Russian]
27. Gambardella J, Sardu C, Sacra C, Santulli G. Quit smoking to outsmart atherogenesis: Molecular mechanisms underlying clinical evidence. Atherosclerosis 2017; 257: 242–5. http://dx.doi.org/10.1016/j.atherosclerosis. 2016.12.010
28. De Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012; 367: 1397–406.
29. Bell JA, Hamer M, Sabia S et al. The natural course of healthy obesity over 20 years. J Am Coll Cardiol 2015; 65: 101–2.
30. Shal'nova S.A., Deev A.D., Balanova Iu.A. i dr. Dvadtsatiletnie trendy ozhireniia i arterial'noi gipertonii i ikh assotsiatsii v Rossii. Kardiovaskuliarnaia terapiia i profilaktika. 2017; 4: 4–10. [in Russian]
31. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults JACC, 2017. DOI: 10.1016/j.jacc.2017.11.006.
32. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.
33. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290–300.
34. Metel'skaia V.A., Shal'nova S.A., Deev A.D. i dr. Analiz rasprostranennosti pokazatelei, kharakterizuiushchikh aterogennost' spektra lipoproteinov, u zhitelei Rossiiskoi Federatsii (po dannym issledovaniia ESSE-RF). Profilakticheskaia meditsina. 2016; 19 (1): 15–23. [in Russian]
35. Kotseva K, Wood D, De Bacquer D et al. EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636–48.
36. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J 2016; 37: 2999–3058. DOI: 10.1093/eurheartj/ ehw272.
37. Ezhov M.V., Sergienko I.V., Aronov D.M. i dr. Diagnostika i korrektsiia narushenii lipidnogo obmena s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii IV peresmotra. Ateroskleroz i dislipidemii. 2017; 3: 5–22. [in Russian]
38. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46: 1855–62.
39. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–97.
40. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81.
41. Preis SR, Hwang SJ, Coady S et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009; 119: 1728–35.
42. Chodick G, Shalev V, Gerber Y et al. Longterm persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30: 2167–79.
43. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C–60C.
44. Semenova A.E., Sergienko I.V. Mesto pitavastatina v lechenii i profilaktike serdechno-sosudistykh zabolevanii. Ateroskleroz i dislipidemii. 2017; 3: 33–45. [in Russian]
45. Catapano AL. Pitavastatin: a different pharmacological profile. Clin Lipidol 2012; 7 (3): 3–9.
46. Katapano A., Kukharchuk V.V., Sergienko I.V. i dr. Pitavastatin – sovremennyi statin dlia korrektsii dislipidemii i riska serdechno-sosudistykh oslozhnenii. Rezoliutsiia ekspertnogo soveta. Ateroskleroz i dislipidemii. 2017; 2: 104–6. [in Russian]
47. Pelliccia F, Rosano G, Marazzi G et al. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual anti platelet therapy. Circ J 2014; 78 (3): 679–84.
48. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009; 25: 2755–64.
49. Teramoto T. Pitavastatin: cl inical effects from the LIVES Study. Atheroscler (Suppl.) 2011; 12: 285–8.
50. Maruyama T, Takada M, Nishibori Y et al. Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study. Circ J 2011; 75 (8): 1951–9.
51. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Livazo. RU LP-002855–090215. [in Russian]
52. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dysli pidemia. Clin Lipidol 2009; 4 (3): 291–302.
53. Borghi C, Cicero AFG. Which statin is the ideal statin for poly medicated patients? Clin Lipidol 2012; 7 (3): s11–s6.
54. Hiro T, Kimura T, Morimoto T et al; JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009; 54: 293–302.
55. Kodama K, Komatsu S, Ueda Y et al. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound – the TOGETHAR trial. Circ J 2010; 74 (9): 1922–8.
56. Maruyama T, Takada M, Nishibori Y et al. Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study. Circ J 2011; 75 (8): 1951–9.
57. Takayama K, Taki W, Toma N et al. Effect of Pitavastatin on Preventing Ischemic Complications with Carotid Artery Stenting: A Multicenter Prospective Study – EPOCH-CAS Study. Cardiovasc Intervent Radiol 2014; 37: 1436–43. DOI: 10.1007/s00270-013-0813-x.
58. Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholestero – lemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther 2011; 9 (5): 555–62.
59. Kurihara Y, Douzono T, Kawakita K et al. A large-scale, prospective post-marketing surveillance of pitavastatin (LIVALOTM Tablet) – Drug use investigation. Jpn Pharmacol Ther 2007; 35: 9–40.
60. Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv Ther 2011; 28 (9): 799–810.
61. Giliarevskii S.R., Kuz'mina I.M., Golshmid M.V. i dr. Primenenie pitavastatina u lits pozhilogo i starcheskogo vozrasta: optimal'noe sootnoshenie pol'zy i riska. Aterotromboz. 2016; 2: 106–16. [in Russian]

М.Г.Бубнова

ФГБУ «Национальный медмцинский исследовательский центр профилактической медицины» Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3
mbubnova@gnicpm.ru

________________________________________________

M.G.Bubnova

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation. 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3
mbubnova@gnicpm.ru